News for BNTC Stock

Benitec Biopharma Releases Third Quarter 2025 Financial Results Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference Benitec Biopharma to Participate in Upcoming Conferences in March Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference Benitec Biopharma to Participate in Upcoming Conferences in January and February Benitec Biopharma to Participate in Upcoming Investor Conferences in December Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference Benitec Biopharma Announces Updated Investor Webcast Information Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update Benitec Biopharma to Participate in the Citizens JMP Life Science Conference Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024 Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023 Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update Benitec Biopharma to Present at the OPMD International Conference Benitec Biopharma to Present at the JMP Securities Life Sciences Conference Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update Benitec Biopharma Releases Q3 2022 Financial Results Benitec Biopharma Discloses Q2 2022 Financial Results Benitec Biopharma Discloses Q1 2022 Financial Results Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022 Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022 Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock Benitec Biopharma Announces Successful Results from the Interim Analysis of the BB-301 Pilot Dosing Study Benitec Biopharma Announces 2020 Annual Stockholder Meeting Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares Benitec Biopharma Announces Pricing of $10.0 Million Public Offering Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference